Keywords: Elan Corp, Biogen Idec, Tysabri, MUltiple sclerosis, 2012 financial results

Elan sells its Tysabri rights to Biogen; posts 2012 financials

Article | 07 February 2013

Print This

Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec (Nasdaq: BIIB) has agreed to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in